Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARD-AXA
2023-505733-28-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rivaroxaban in chronic kidney disease (CKD) (3 arms), sponsored by CHRU Tours. Primary endpoint: Area under the concentration–time curve (AUC) of rivaroxaban and anti-Xa activity. Planned start Apr 2024; status: authorised.
02
Drugs
rivaroxaban
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-505733-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505733-28-00.